ReShape Lifesciences Inc (NASDAQ: RSLS) specializes in weight-loss and metabolic health solutions, offering a range of products and services for obesity and metabolic disease management. Its flagship Lap-Band System is a minimally invasive, long-term treatment for obesity, providing an alternative to more complex surgical procedures like gastric bypass or sleeve gastrectomy.

• ReShape Lifesciences Secures Diabetes Treatment Patent: ReShape Lifesciences® has received a Notice of Allowance from the USPTO for its patent application on a Diabetes Neuromodulation system. The patent, valid until April 12, 2039, covers technology using simultaneous multi-site vagus nerve modulation to improve glycemic control. This system integrates ReShape’s proprietary vBloc™ technology with vagus nerve stimulation to treat Type 2 diabetes, a condition closely linked to obesity.
• ReShape Lifesciences Expands Lap-Band® Distribution to Canada: ReShape Lifesciences® has entered into a distribution agreement with Liaison Medical for the distribution of its next-generation Lap-Band® 2.0 FLEX and Tubing Kit in Canada.
• ReShape Lifesciences Announces Pricing of Public Offering: ReShape Lifesciences® has priced its public offering of 2,575,107 units at $2.33 per unit. Each unit includes one common share (or a pre-funded warrant) and one warrant to purchase a common share.
• ReShape Lifesciences Granted Israeli Patent for Diabetes Neuromodulation Technology: ReShape Lifesciences® has received an international patent from the State of Israel Patent Office for its Diabetes Neuromodulation technology. Patent Number 277949, valid until December 4, 2039, covers the use of simultaneous multi-site vagus nerve modulation to improve glycemic control. The system integrates the company's proprietary vBloc™ technology with vagus nerve stimulation to treat Type 2 diabetes, a condition linked to obesity.
• ReShape Lifesciences and Vyome Therapeutics Announce Merger Agreement: ReShape Lifesciences Inc. and Vyome Therapeutics, Inc. have provided an update on their definitive all-stock merger agreement. The combined company will focus on developing Vyome’s immuno-inflammatory assets and exploring opportunities between the Indian innovation corridor and the U.S. market. ReShape also shared an update on its asset purchase agreement with Biorad Medisys.
  

Technical Observation (on the daily chart):

The stock is in a strong downtrend, trading well below its 21-day and 50-day moving averages, with a massive 67% drop on the latest trading day. A significant volume spike suggests heavy selling pressure, while the RSI at 41.83 indicates it's approaching oversold territory. No clear reversal signals are present, but a short-term bounce could occur if buying interest emerges. The trend remains bearish unless the stock reclaims key moving averages.

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘Watch’ rating has been given to ReShape Lifesciences Inc (NASDAQ: RSLS) at the current market price of USD 0.52 as of April 02,2025 at 08:05 AM PST. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is April 02,2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.